Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Cihan Ay, Katarina D. Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, Christa Firbas, Peter Quehenberger, Petra Jilma-Stohlawetz, James C. Gilbert, Shuhao Zhu, Martin Beliveau, Franz Koenig, Alfonso Iorio, Bernd Jilma, Ulla Derhaschnig, Ingrid Pabinger

Blood (2023) 141 (10): 1147–1158.

https://doi.org/10.1182/blood.2022016571

Published: 2023

Includes: Supplemental data

Journal Articles

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C. Parry, James C. Gilbert, Bernd Jilma

Blood (2019) 133 (9): 893–901.

https://doi.org/10.1182/blood-2018-06-856930

Published: 2019

Includes: Supplemental data

Journal Articles

Reversal Strategy For Antagonizing The P2Y12-Inhibitor Ticagrelor By Platelet Concentrates

Hobl Eva-Luise, PhD, Petra Jilma-Stohlawetz, MD, Ulla Derhaschnig, MD, Schoergenhofer Christian, MD, Michael Schwameis, MD, Bernd Jilma, MD

Blood (2013) 122 (21): 1153.

https://doi.org/10.1182/blood.V122.21.1153.1153

Published: 2013

Journal Articles

Effects of Strong P2Y12 Receptor Inhibition by Prasugrel on Platelet Inhibition During Endotoxemia: A Randomized Controlled Trial

Alexander O Spiel, MD, Ulla Derhaschnig, MD, Petra Jilma-Stohlawetz, MD, Bernd Jilma, MD

Blood (2011) 118 (21): 1245.

https://doi.org/10.1182/blood.V118.21.1245.1245

Published: 2011

Journal Articles

Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia

Ulla Derhaschnig, Rosemarie Reiter, Paul Knöbl, Magdalena Baumgartner, Priska Keen, Bernd Jilma

Blood (2003) 102 (6): 2093–2098.

https://doi.org/10.1182/blood-2003-02-0416

Published: 2003

NARROW

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Reversal Strategy For Antagonizing The P2Y12-Inhibitor Ticagrelor By Platelet Concentrates

Effects of Strong P2Y12 Receptor Inhibition by Prasugrel on Platelet Inhibition During Endotoxemia: A Randomized Controlled Trial

Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia

Email alerts

ASH Publications

American Society of Hematology

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Reversal Strategy For Antagonizing The P2Y12-Inhibitor Ticagrelor By Platelet Concentrates

Effects of Strong P2Y12 Receptor Inhibition by Prasugrel on Platelet Inhibition During Endotoxemia: A Randomized Controlled Trial

Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only